Background: The HBeAg-positive chronic hepatitis B is the type of chronic hepatitis with active virus replication, has high viral load and difficult to treat. We evaluate the effects of treatment with tenofovir in HBeAg-positive chronic hepatitis B patients. Aims: Evaluate the treatment results in patients with HBeAg-positive chronic hepatitis B. Patients and methodes: HBeAg-positive chronic hepatitis B patients over 15 yrs treated at Hue University Hospital from Jan. 2012 to Dec. 2013. Results: Most of symptoms disappeared after 12 months. More than 85% patients have biochemical response. 81.8% patients have undetectable HBV DNA. Rate of HBV DNA decrease according to the baseline viral load. After 12 months 27.3% patients loss HBeAg and 20.5% have anti-HBe. Conclusions: Clinical and biochemical response were relatively high. 81.8% patients have undetectable HBV DNA. After 12 months 27.3% patients loss HBeAg and 20.5% have anti-HBe. Key words: HBeAg-positive chronic hepatitis B, HBV DNA
Initial combining lamivudine and adefovir dipivoxil and lamivudine/entecavir monotherapy in hepatitis B e antigen-positive chronic hepatitis B with high viral load
